BioNTech sets IPO pricing terms
BioNTech SE, a German biotech company focused on treating cancer and other serious diseases, is planning on raising about $250 million for its IPO after pricing its 13.2 million shares at a price between $18 and $20 per share. The company plans on trading the stock on the NASDAQ under the ticker symbol "BNTX." J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink are the lead underwriters. BioNTech's investors include Fidelity Management & Research Company.
25 September 2019•3 mins read
